Recent news on Oncaspar

Enzon Reports First Quarter 2007 Results  -  May 2, 2007
American Digital Networks (press release),The Company continues to experience growth in its oncology products, Oncaspar and DepoCyt. The decrease in sales for the product segment this quarter is

Enzon Announces Timing of Annual Meeting of Shareholders  -  Apr 24, 2007
Business Wire (press release),Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing

FDA Grants Full Approval for DepoCyt for the Treatment of ...  -  Apr 20, 2007
PharmaLive.com (press release),Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing

Enzon's PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 18, 2007
PipelineReview.com (press release),Currently, there are five marketed biologic products that utilize our proprietary PEG platform, two of which Enzon markets, Adagen(R) and Oncaspar(R),

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
PipelineReview.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and DepoCyt(R) in the United States. In addition, Enzon also receives royalties

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
Business Wire (press release),Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and DepoCyt® in the United States. In addition, Enzon also receives royalties on sales

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
PharmaLive.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt(R) in the United States. In addition, Enzon also receives royalties

Enzon Reports 2006 Financial Results and Accomplishments  -  Feb 13, 2007
Genetic Engineering News (press release),The Company secured the future supply of L-asparaginase, the active ingredient used in the production of Oncaspar, along with an agreement to transfer of

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 4, 2007
dBusinessNews Newark (press release),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Genetic Engineering News (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties

Intravenous Oncaspar® Safe and Effective in Children with ALL  -  Jan 9, 2007
Cancer Consultants (press release),Researchers from the Dana-Farber Cancer Institute have reported that Oncaspar® (pegaspargase) can be safely given intravenously (IV) to children with acute

Enzon Pharmaceuticals Secures Supply of Oncaspar  -  Jan 4, 2007
Business New Jersey (subscription),Oncaspar is a form of L-asparaginase enhanced with Enzon’s PEGylation technology for the treatment of Acute Lymphoblastic Leukemia or ALL.

Intravenous Oncaspar® is Well Tolerated in Adults with ALL  -  Jan 4, 2007
Cancer Consultants (press release),Researchers from the University of Southern California have reported that multiple doses of Oncaspar® (Peg-Asparaginase) can be given safely with minimal

Market Report -- In Play (ENZN)  -  Jan 4, 2007
MSN MoneyEnzon says secures supply of Oncaspar Co announces it entered into an agreement with Ovation Pharmaceuticals for the supply of the active ingredient used in

Enzon Secures Supply for its Leukemia Treatment  -  Jan 4, 2007
Genetic Engineering News (press release),Oncaspar is a form of L-asparaginase enhanced with Enzon’s PEGylation technology. The deal was signed after the expiration of a previous agreement between

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
American Digital Networks (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
Business New Jersey (subscription),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional